62846 Efficacy of deucravacitinib in psoriasis by baseline total body surface area: post hoc analysis of the randomized, double-blind, placebo-controlled, phase 3b/4 PSORIATYK Scalp trial
Recommended Citation
Blauvelt A, Hoffman M, Stein Gold LF, Bagel J, Lebwohl M, Napoli A, Cheng C, Dyme R, Balagula E, Griffiths CE. 62846 Efficacy of deucravacitinib in psoriasis by baseline total body surface area: post hoc analysis of the randomized, double-blind, placebo-controlled, phase 3b/4 PSORIATYK Scalp trial. J Am Acad Dermatol 2025; 93:AB191.
Document Type
Conference Proceeding
Publication Date
9-1-2025
Publication Title
J Am Acad Dermatol
Abstract
Introduction: Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is approved in multiple countries for treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. In the phase 3b/4, PSORIATYK SCALP (NCT05478499) trial, deucravacitinib was superior to placebo at Week 16 in patients with moderate to severe scalp psoriasis, including those with more limited overall psoriasis.1 This analysis reports efficacy in overall body psoriasis by baseline total body surface area (BSA) involvement. Methods: Outcomes at Week 16, analyzed by BSA involvement of 3%-10% or >10%, included static Physician Global Assessment score of 0 (clear) or 1 (almost clear) with a ≥2-point reduction from baseline (sPGA 0/1) and adjusted mean change from baseline in PASI. Nonresponder imputation (binary outcomes) and modified baseline observation carried forward (continuous outcomes) were used for patients who had missing data. Analyses are post hoc; P values are nominal. Results: Baseline BSA-defined subgroups were 3%-10% (n=70 vs n=38) and >10% (n=33 vs n=13) for deucravacitinib vs placebo, respectively. Week 16 sPGA 0/1 response rates were comparable in 3%-10% and >10% BSA subgroups, with higher proportions among patients treated with deucravacitinib versus placebo (42.9% vs 5.3% and 57.6% vs 0%, respectively; P<0.001 for both). Similarly, decreases in adjusted mean PASI were greater with deucravacitinib than with both 3%-10% (−3.7 vs −1.0, respectively) and >10% (−13.2 vs −2.2) BSA subgroups (P<0.0001 for both). Conclusion: Deucravacitinib was efficacious in improving psoriasis in patients with a wide range of total BSA involvement.
Volume
93
First Page
AB191
